Equity

BTEC

iShares Nasdaq US Biotechnology UCITS ETF

Overview

Important Information: Capital at Risk. The value of investments and the income from them can fall as well as rise and are not guaranteed. Investors may not get back the amount originally invested.

Important Information: The value of your investment and the income from it will vary and your initial investment amount cannot be guaranteed. The value of equities and equity-related securities can be affected by daily stock market movements.

All currency hedged share classes of this fund use derivatives to hedge currency risk. The use of derivatives for a share class could pose a potential risk of contagion (also known as spill-over) to other share classes in the fund. The fund’s management company will ensure appropriate procedures are in place to minimise contagion risk to other share class. Using the drop down box directly below the name of the fund, you can view a list of all share classes in the fund – currency hedged share classes are indicated by the word “Hedged” in the name of the share class. In addition, a full list of all currency hedged share classes is available on request from the fund’s management company
Loading

Performance

Performance

Chart

View full chart

This chart shows the fund's performance as the percentage loss or gain per year over the last 6 years.

  2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Total Return (%) -9.2 24.6 25.9 -0.4 -10.5 4.2
Benchmark (%) -9.0 24.9 26.2 -0.2 -10.4 4.3
  From
30-Sept-2019
To
30-Sept-2020
From
30-Sept-2020
To
30-Sept-2021
From
30-Sept-2021
To
30-Sept-2022
From
30-Sept-2022
To
30-Sept-2023
From
30-Sept-2023
To
30-Sept-2024
Total Return (%)

as of 30/Sept/2024

36.33 19.71 -25.59 5.37 21.15
Benchmark (%)

as of 30/Sept/2024

36.66 19.98 -25.46 5.53 21.29
  1y 3y 5y 10y Incept.
26.42 -1.90 7.01 - 4.37
Benchmark (%) 26.60 -1.75 7.21 - 4.58
  YTD 1m 3m 6m 1y 3y 5y 10y Incept.
6.75 -2.50 -3.90 11.95 26.42 -5.59 40.33 - 35.08
Benchmark (%) 6.87 -2.47 -3.87 12.05 26.60 -5.15 41.62 - 36.98
Past performance is not a guide to future performance and should not be the sole factor of consideration when selecting a product. Performance data is based on the net asset value (NAV) of the ETF which may not be the same as the market price of the ETF. Individual shareholders may realise returns that are different to the NAV performance

The figures shown relate to past performance. Past performance is not a reliable indicator of future performance. Markets could develop very differently in the future. It can help you to assess how the fund has been managed in the past

Share Class and Benchmark performance displayed in USD, hedged share class benchmark performance is displayed in USD.

Performance is shown on a Net Asset Value (NAV) basis, with gross income reinvested where applicable. Performance data is based on the net asset value (NAV) of the ETF which may not be the same as the market price of the ETF. Individual shareholders may realize returns that are different to the NAV performance.

The return of your investment may increase or decrease as a result of currency fluctuations if your investment is made in a currency other than that used in the past performance calculation. Source: Blackrock

Key Facts

Key Facts

Net Assets of Share Class
as of 25/Nov/2024
USD 485,422,198
Share Class Launch Date
19/Oct/2017
Share Class Currency
USD
Asset Class
Equity
SFDR Classification
Other
Total Expense Ratio
0.35%
Use of Income
Accumulating
Domicile
Ireland
Rebalance Frequency
Quarterly
UCITS
Yes
Fund Manager
BlackRock Asset Management Ireland Limited
Custodian
State Street Custodial Services (Ireland) Limited
Bloomberg Ticker
BTEC LN
ISA Eligibility
Yes
Net Assets of Fund
as of 25/Nov/2024
USD 521,238,955
Fund Launch Date
19/Oct/2017
Fund Base Currency
USD
Benchmark Index
NASDAQ Biotechnology Index (Net Total Return)
Shares Outstanding
as of 25/Nov/2024
72,850,960
ISIN
IE00BYXG2H39
Securities Lending Return
as of 30/Sept/2024
0.08%
Product Structure
Physical
Methodology
Replicated
Issuing Company
iShares IV plc
Administrator
SSB-STATE STREET DUBLIN FUND ACCOUNTING
Fiscal Year End
31 May
SIPP Available
Yes
UK Reporting Status
Yes

Portfolio Characteristics

Portfolio Characteristics

Number of Holdings
as of 22/Nov/2024
214
Benchmark Ticker
XNBINNR
3y Beta
as of 31/Oct/2024
0.999
P/B Ratio
as of 22/Nov/2024
3.47
Benchmark Level
as of 25/Nov/2024
USD 1,435.94
Standard Deviation (3y)
as of 31/Oct/2024
17.44%
P/E Ratio
as of 22/Nov/2024
20.89

Ratings

Registered Locations

Registered Locations

  • Austria

  • Denmark

  • Finland

  • France

  • Germany

  • Ireland

  • Italy

  • Luxembourg

  • Netherlands

  • Norway

  • Portugal

  • Saudi Arabia

  • Spain

  • Sweden

  • Switzerland

  • United Kingdom

Holdings

Holdings

Issuer Ticker Name Sector Asset Class Market Value Weight (%) Notional Value Nominal ISIN Price Location Exchange Market Currency
Detailed Holdings and Analytics contains detailed portfolio holdings information and select analytics.

Exposure Breakdowns

Exposure Breakdowns

as of 22/Nov/2024

% of Market Value

Type Fund
Allocations are subject to change.

Securities Lending

Securities Lending

Securities lending is an established and well regulated activity in the investment management industry. It involves the transfer of securities (such as shares or bonds) from a Lender (in this case, the iShares fund) to a third-party (the Borrower). The Borrower will give the Lender collateral (the Borrower’s pledge) in the form of shares, bonds or cash, and will also pay the Lender a fee. This fee provides additional income for the fund and thus can help to reduce the total cost of ownership of an ETF.

 

At BlackRock, securities lending is a core investment management function with dedicated trading, research and technology capabilities. The lending programme is designed to deliver superior absolute returns to clients, whilst maintaining a low risk profile. Funds participating in securities lending retain 62.5% of the income, while BlackRock receives 37.5% of the income and covers all the operational costs resulting from securities lending transactions.

 

  From
30-Sept-2014
To
30-Sept-2015
From
30-Sept-2015
To
30-Sept-2016
From
30-Sept-2016
To
30-Sept-2017
From
30-Sept-2017
To
30-Sept-2018
From
30-Sept-2018
To
30-Sept-2019
From
30-Sept-2019
To
30-Sept-2020
From
30-Sept-2020
To
30-Sept-2021
From
30-Sept-2021
To
30-Sept-2022
From
30-Sept-2022
To
30-Sept-2023
From
30-Sept-2023
To
30-Sept-2024
Securities Lending Return (%) 0.02 0.04 0.02 0.04 0.03 0.08
Average on-loan (% of AUM) 5.68 9.11 9.50 6.44 5.88 13.18
Maximum on-loan (% of AUM) 10.00 10.00 10.34 9.95 10.32 20.10
Collateralisation (% of Loan) 111.23 109.64 109.27 110.29 111.63 111.16
The above table summarises the lending data available for the fund.

The information in the Lending Summary table will not be displayed for the funds that have participated in securities lending for less than 12 months. The figures shown relate to past performance. Past performance is not a reliable indication of current or future results.
BlackRock’s policy is to disclose performance information quarterly subject to a one-month delay. This means that returns from 01/01/2019 to 31/12/2019 can be publicly disclosed from 01/02/2020.

Maximum on-loan figure may increase or decrease over time.

With securities lending there is a risk of loss should the borrower default before the securities are returned, and due to market movements, the value of collateral held has fallen and/or the value of the securities on loan has risen.
as of 22/Nov/2024
Ticker Name Asset Class Weight % ISIN SEDOL Exchange Location
Collateral Holdings shown on this page are provided on days where the fund participating in securities lending had an open loan.

The information in the Collateral Holdings table relates to securities obtained in the collateral basket under the securities lending programme for the fund in question. The information contained in this material is derived from proprietary and non-proprietary sources deemed by BlackRock to be reliable, is not necessarily all inclusive and is not guaranteed as to accuracy. Reliance upon information in this material is at the sole discretion of the reader. The primary risk in securities lending is that a borrower will default on their commitment to return lent securities while the value of the liquidated collateral does not exceed the cost of repurchasing the securities and the fund suffers a loss in respect of the short-fall.
The below table shows the Loan/Collateral Combinations and Collateral Levels for our European Lending funds.
Collateral Types
Loan Type Equities Government, Supranational and Agency Bonds Cash (Not for Reinvestment)
Equities 105%-112% 105%-106% 105%-108%
Government Bonds 110%-112% 102.5%-106% 102.5%-105%
Corporate Bonds 110%-112% 104%-106% 103.5%-105%

We also accept selected physically replicating Equity, Government Bond, Credit and Commodity ETFs as collateral.

Collateral parameters depend on the collateral and the loan combination, and the over collateralisation level may range from 102.5% to 112%. In this context, “Over Collateralisation” means that the aggregate market value of collateral taken will exceed the overall on-loan value. Collateral parameters are reviewed on an ongoing bases and are subject to change.
With securities lending there is a risk of loss should the borrower default before the securities are returned, and due to market movements, the value of collateral held has fallen and/or the value of the securities on loan has risen.

Listings

Listings

Exchange Ticker Currency Listing Date SEDOL Bloomberg Ticker RIC
London Stock Exchange BTEC USD 23/Oct/2017 BYXG2H3 BTEC LN BTEC.L
Xetra 2B70 EUR 23/Nov/2017 BDFBMJ1 2B70 GY BTEC.DE
London Stock Exchange BTEK GBP 23/Oct/2017 BYZQ0Y4 BTEK LN BTEK.L
Bolsa Mexicana De Valores BTEC1 MXN 23/May/2019 BKDSSJ5 BTEC1N MM BTEC1N.MX
SIX Swiss Exchange BTEC USD 16/Mar/2018 BD1JXY1 BTEC SW BTEC.S

Literature

Literature